Skip to main content
. 2022 Apr 8;12(4):929. doi: 10.3390/diagnostics12040929

Table 1.

Summary of main manuscripts focused on the role of 18F-FDG PET/CT for the imaging of advanced MM.

Authors Year Type of Study Setting Number of
Patients
Comment
Gulec et al. [18] 2003 Retrospective, single-center Impact on clinical management n = 59 18F-FDG PET/CT detected additional lesions with respect to conventional imaging (total body CT) in the majority of patients and significantly impacted on therapeutic decision.
Querellou et al. [19] 2010 Retrospective, single-center Additional value of
lower limbs scan in MM patients
n = 122 In patients without known or suspected MM focuses on the lower limbs, additional scan did not add significant information or impacted on clinical managment.
Pfluger et al. [20] 2011 Retrospective,
Single-center
Contribution of contrast-enhanced CT (ceCT) for PET/CT MM imaging n = 50 PET/CT and PET/ceCT equally performed in advanced MM, especially in terms of specificity, therefore the use of conventional PET/CT (no-contrast media) modality is justified.
Bastiaannet et al. [21] 2012 Prospective,
Single-center
Prognostic impact of PET-derived parameter, SUVmax n = 80 In MM at stage IIIB, SUVmax measured on metastatic nodes before surgery can be used to patients prognostic stratification.
Holtkamp et al. [22] 2020 Prospective,
Single-center
Staging and follow-up in patients with in-transit or satellite MM metastases n = 25 PET/CT upstaged 4 out of 25 patients (16%) therefore leading to a change in clinical management. Furthermore, PET/CT detected the onset of distant metastases during follow-up in 10 cases within 6 months from diagnosis.
Klingestein et al. [23] 2010 Retrospective,
Single-center
Restaging and follow-up of uveal melanoma n = 11 PET/CT correctly identified metastases to liver, lungs, nodes and adrenal glands.
Cohen et al. [24] 2018 Retrospective,
Single-center
Staging uveal melanoma n = 108 PET/CT combined with abdominal ultrasonography resulted positive for metastases in 3 cases of uveal melanoma and identified a second primary malignancy in the 9% of the examined subjects.